Back to News
Market Impact: 0.35
Corcept Therapeutics Incorporated Reports Third Quarter 2026 Revenue of $340.5 million
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Corcept Therapeutics reported third-quarter 2026 revenue of $340.5 million, up 64% from the same period in 2025. The article text is truncated while beginning to describe revenue from Korlym and authorized generic products, so no further breakdown or profitability figures are available.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
CORT0.70
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales